Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monia Marchetti

Showing results (81-90 of 123) with videos related to

Pageof 13
Sort By:
Hemasphere|December 31, 2025
Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational studyGiovanni Caocci, Alessandro Costa, Francesca Palandri, et al.
Blood Advances|November 13, 2024
Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter studyBruno Fattizzo, Alfredo Marchetti, Alessandro Bosi, et al.
Haematologica|July 11, 2019
HIF-1α is over-expressed in leukemic cells from <i>TP53</i>-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemiaValentina Griggio, Candida Vitale, Maria Todaro, et al.
Frontiers in Oncology|December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus studyAndrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
Hematological Oncology|March 19, 2021
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working GroupGian Matteo Rigolin, Francesco Cavazzini, Alfonso Piciocchi, et al.
Blood|March 2, 2021
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugsCandida Vitale, Chiara Salvetti, Valentina Griggio, et al.
Annals of Hematology|July 18, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study designValerio De Stefano, Francesco Passamonti, Francesca Palandri, et al.
European Journal of Haematology|July 20, 2024
Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET surveyBruno Fattizzo, Valentina Carrai, Monica Crugnola, et al.
Blood|April 16, 2025
International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC RecommendationsAdam S Kittai, Monia Marchetti, Othman Al-Sawaf, et al.
Pageof 13

Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
Hemasphere|December 31, 2025
Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational studyGiovanni Caocci, Alessandro Costa, Francesca Palandri, et al.
Blood Advances|November 13, 2024
Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter studyBruno Fattizzo, Alfredo Marchetti, Alessandro Bosi, et al.
Haematologica|July 11, 2019
HIF-1α is over-expressed in leukemic cells from <i>TP53</i>-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemiaValentina Griggio, Candida Vitale, Maria Todaro, et al.
Frontiers in Oncology|December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus studyAndrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
Hematological Oncology|March 19, 2021
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working GroupGian Matteo Rigolin, Francesco Cavazzini, Alfonso Piciocchi, et al.
Blood|March 2, 2021
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugsCandida Vitale, Chiara Salvetti, Valentina Griggio, et al.
Annals of Hematology|July 18, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study designValerio De Stefano, Francesco Passamonti, Francesca Palandri, et al.
European Journal of Haematology|July 20, 2024
Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET surveyBruno Fattizzo, Valentina Carrai, Monica Crugnola, et al.
Blood|April 16, 2025
International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC RecommendationsAdam S Kittai, Monia Marchetti, Othman Al-Sawaf, et al.
Pageof 13